Neuraminidase-IN-18, identified by its CAS number 2935407-32-0, is a chemical compound that serves as an inhibitor of neuraminidase, an enzyme critical for the replication of certain viruses, particularly influenza. This compound is part of a broader class of antiviral agents designed to impede the activity of neuraminidase, thereby preventing the release of new viral particles from infected cells. Characteristically, Neuraminidase-IN-18 exhibits a specific binding affinity to the active site of the neuraminidase enzyme, which is essential for its inhibitory action. The compound's structure typically includes functional groups that enhance its interaction with the enzyme, contributing to its efficacy. Additionally, it may possess favorable pharmacokinetic properties, such as good oral bioavailability and metabolic stability, making it a candidate for therapeutic use. Research into Neuraminidase-IN-18 may also explore its safety profile, potential side effects, and effectiveness against various strains of influenza, contributing to the development of effective antiviral therapies.

Neuraminidase-IN-18

2935407-32-0: Neuraminidase-IN-18, identified by its CAS number 2935407-32-0, is a chemical compound that serves as an inhibitor of neuraminidase, an enzyme critical for the replication of certain viruses, particularly influenza. This compound is part of a broader class of antiviral agents designed to impede the activity of neuraminidase, thereby preventing the release of new viral particles from infected cells. Characteristically, Neuraminidase-IN-18 exhibits a specific binding affinity to the active site of the neuraminidase enzyme, which is essential for its inhibitory action. The compound's structure typically includes functional groups that enhance its interaction with the enzyme, contributing to its efficacy. Additionally, it may possess favorable pharmacokinetic properties, such as good oral bioavailability and metabolic stability, making it a candidate for therapeutic use. Research into Neuraminidase-IN-18 may also explore its safety profile, potential side effects, and effectiveness against various strains of influenza, contributing to the development of effective antiviral therapies.

<p>Neuraminidase-IN-18 (compound N5), a novel polyheterocyclic neuraminidase (NA) inhibitor, demonstrates significant inhibitory activity against H5N1 NA, with an IC 50 of 0.14 μM against the wild-type H5N1 NA and 0.27 μM against the H5N1-H274Y mutant NA. This compound effectively binds to NAs, inhibiting influenza virus replication at the cellular level [1].</p>

CAS 2935407-32-0

Neuraminidase-IN-18

Neuraminidase-IN-18

Ref: TM-T86997